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a b s t r a c t
As prostate tumor cell growth depends on hormones, androgen ablation is an effective therapy for
prostate cancer (PCa). However, progression of PCa cells to androgen independent growth (castrate
resistant prostate cancer, CRPC) results in relapse and mortality. Hypoxia, a microenvironment of low
oxygen that modiﬁes the activity of PCa regulatory proteins including the androgen receptor (AR), plays
a critical role in progression to CRPC. Therapies targeting hypoxia and the AR may lengthen the time to
CRPC progression thereby increasing survival time of PCa patients. Mammalian Orthoreovirus (MRV) has
shown promise for the treatment of prostate tumors in vitro and in vivo. In this study, we found that MRV
infection induces downregulation of proteins implicated in CRPC progression, interferes with hypoxia-
induced AR activity, and induces apoptosis in androgen dependent cells. This suggests MRV possesses
traits that could be exploited to create novel therapies for the inhibition of progression to CRPC.
& 2015 Elsevier Inc. All rights reserved.
Introduction
PCa is the second most common cancer resulting in death in men
in the United States (Siegel et al., 2014). The growth and differentia-
tion of prostate glands depends on androgens, testosterone and
dihydrotestosterone (DHT). Growth-quiescent maintenance of the
organ occurs in the presence of high levels of testosterone after
puberty, but upon development, prostate tumors become dependent
on androgen for growth. The androgen receptor (AR), a ligand-
activated transcription factor, mediates androgen signaling in the cell,
making it a key protein in PCa progression (Heinlein and Chang,
2004). Upon androgen binding, the AR translocates into the nucleus
and, as a homodimer, binds to speciﬁc sequences (androgen response
elements or ARE) in the regulatory elements of target genes promot-
ing their transcription. AR-dependent transcription requires the
recruitment of coactivator proteins by AR, which increase the
transcription rate and facilitate the growth of cancerous cells (Bevan
and Parker, 1999). Thus androgen deprivation using either anti-
androgens (such as bicalutamide), which directly inhibit the AR, or
chemicals (such as Goserelin acetate) which block androgens, is an
effective treatment for PCa. This treatment arrests the disease in the
majority of cases, as evidenced by decrease in prostate speciﬁc
antigen (PSA), a well-accepted marker for the diagnosis and prognosis
of PCa, and a functional biomarker of AR activation (Lieberman, 2004).
However, relapse in the form of androgen-independent PCa tumor
growth occurs usually within 3 years following the onset of androgen
deprivation. This androgen independent growth phase of PCa, also
known as castration-resistant prostate cancer (CRPC), responds poorly
to currently available treatments such as docetaxel and prednisone
and is associated with metastasis and poor prognosis (Feldman and
Feldman, 2001). Establishing the AR as a valid therapeutic target for
CRPC changed the focus of drug development towards AR targeting
and drugs such as Enzalutamide, which inhibits AR signaling were
recently approved for treating CRPC (Attard et al., 2005).
Hypoxia is a condition of decreased oxygen levels that occurs
within microenvironments of solid tumors, arising due to rapidly
dividing tumor cells, which evade the blood supply. In PCa, hypoxia
leads to increased AR activity and sensitivity leading to PCa growth
under very low androgen concentrations (Park et al., 2006). Relapsed
CRPC strongly expresses hypoxia inducible factor 1α (HIF-1α), the
master transcriptional regulator of the cellular hypoxic response
(Ming et al., 2013; Ranasinghe et al., 2014). The results of several
studies suggest that HIF-1α works with AR to activate the expression
of several genes related to tumor angiogenesis, invasion, and progres-
sion and thus has been shown to inﬂuence androgen resistance and
progression to CRPC (Marignol et al., 2008). Another common feature
of androgen independent prostate tumors is the mutation or deletion
of the tumor suppressor gene phosphatase and tensin homolog




0042-6822/& 2015 Elsevier Inc. All rights reserved.
n Corresponding author at: Department of Veterinary Microbiology and Preven-
tive Medicine, College of Veterinary Medicine, Iowa State University, Ames, IA
50011, United States. Tel.: þ1 515 294 4797.
E-mail addresses: pgupta@iastate.edu (P. Gupta-Saraf),
tmeseke@iastate.edu (T. Meseke), clm@iastate.edu (C.L. Miller).
Virology 485 (2015) 153–161
(PTEN) (Li et al., 1997; Zundel et al., 2000). PTEN inhibits the
phosphoinositide 3-kinase/serine threonine protein kinase B (PI3K/
AKT) pathway by dephosphorylating phosphoinositide-3,4,5 tripho-
sphate (PIP3). The PI3K/Akt pathway in turn regulates the stimulation
of cell cycle progression, survival, migration and metabolism. Thus,
the loss of PTEN activity correlates with high Akt activity leading to
apoptosis resistance and tumor growth in PCa (Chen et al., 2001;
Sircar et al., 2009; Yamaguchi and Wang, 2001). Similar to the AR, the
PI3K/Akt signaling pathway is both regulated, and induced, by
hypoxia (Alvarez-Tejado et al., 2001; Ghafar et al., 2003; Jiang et al.,
2001; Zundel et al., 2000).
Mammalian Orthoreovirus (MRV) is a clinically benign oncolytic
virus that preferentially replicates in tumor cells over normal cells.
Successful demonstration of MRV's potent oncolytic activity in many
different cancer types in animal models (Wilcox et al., 2001; Yang et al.,
2004) has resulted in testing the virus as a cancer therapy in a number
of Phase I/II/III human clinical trials. These trials have proven MRV's
efﬁcacy as a safe and applicable therapy for a number of cancer types
where it leads to tumor regression or stabilization in many patients
(Carew et al., 2013; Carlson et al., 2005; Comins et al., 2010; Harrington
et al., 2010; Hingorani et al., 2011; Lal et al., 2009; Stoeckel and Hay,
2006). MRV has been shown to be effective against PCa cells in vitro, in
an in vivo animal model and in human clinical trials (Gujar et al., 2011;
Thirukkumaran et al., 2010; Vidal et al., 2008). Our lab recently
demonstrated that MRV is successful in inducing apoptosis in androgen
independent (DU145) PCa cells grown in normoxic and hypoxic
conditions (Gupta-Saraf and Miller, 2014). Strikingly, we additionally
found that MRV infection induces massive HIF-1α downregulation in
both androgen-dependent and androgen-independent PCa cells via
proteasome mediated degradation and translational inhibition. How-
ever, in prior studies, we did not examine the impact of MRV infection
on androgen-dependent PCa cell survival or expression of proteins that
are involved in progression to androgen independence. As multiple
studies point towards a link between this progression and HIF-1α
activity, for this work, we hypothesized that MRV-induced down-
regulation of HIF-1α may also impact other proteins involved in PCa
progression from androgen dependence to androgen independence.
Thus the objective of this study was to elucidate the effect of MRV
infection on the protein levels and activity of Akt, AR and PSA in
androgen dependent cells growing in normoxic and hypoxic conditions.
Results
MRV infection induces apoptotic cell death in androgen dependent
LNCaP prostate tumor cells
MRV infection is known to induce apoptosis in cells growing
under normoxic conditions, (Clarke et al., 2005) however, growth in
hypoxic conditions leads to apoptosis resistance via upregulation of
anti-apoptotic factors (Baek et al., 2000; Dong et al., 2001; Gerber
et al., 1998) and downregulation of pro-apoptotic factors (Erler et al.,
2004). We previously demonstrated that MRV infection induces
apoptosis in androgen independent DU145 cells by activating both
intrinsic and extrinsic pathways (Gupta-Saraf and Miller, 2014),
however we did not examine the effect of MRV infection on apoptosis
of androgen-dependent LNCaP cells grown in hypoxic conditions. To
determine the effect of hypoxic growth and MRV infection on LNCaP
cell viability, we mock- or MRV-infected cells and allowed them to
incubate for 24 or 48 h under either normoxic or hypoxic conditions.
Cell viability was then measured using the Cell-Titer Blue viability
assay. In these experiments, MRV infection caused signiﬁcantly
reduced viability of normoxic LNCaP cells relative to uninfected cells
as has been previously demonstrated (Thirukkumaran et al., 2010).
MRV infection caused a similar reduction in viability of LNCaP cells
grown under hypoxic conditions (Fig. 1A). There were no signiﬁcant
differences in the amount of cell death induced by hypoxic growth
relative to normoxic growth in either the absence or presence of MRV
infection, suggesting that if growth in hypoxic conditions contributes
to a death resistant phenotype as has been reported, MRV infection is
able to overcome this resistance. To determine if cell death resulting
from MRV infection was due to apoptosis, we repeated these
experiments and measured caspase 3/7 activity. We found signiﬁ-
cantly increased caspase activity in both normoxic and hypoxic
infected samples relative to uninfected samples (Fig. 1B). Again we
found no signiﬁcant differences in caspase 3/7 activity in hypoxic
relative to normoxic samples in either uninfected or MRV-infected
samples. These results show that MRV induces apoptosis and thus
causes cell death in androgen dependent LNCaP cells grown under
both normoxic and hypoxic conditions.
MRV infection induces downregulation of phosphorylated Akt
Akt, in its phosphorylated, active form (P-Akt), is a key
regulator of protection of prostate tumor cells from apoptosis via
inhibition of pro-apoptotic proteins such as Bax and BAD (Datta
et al., 1997; Yamaguchi and Wang, 2001). In LNCaP cells, one allele
of PTEN, a primary negative regulator of Akt activity, is deleted and
the other is mutated, resulting in high Akt phosphorylation and
apoptosis resistance (Li et al., 1997; Sircar et al., 2009). Hypoxia, via
HIF-1α, has also been linked to activating Akt phosphorylation and
promoting cell survival (Alvarez-Tejado et al., 2001; Dai et al.,
2008; Zundel et al., 2000). Since we previously demonstrated that
MRV infection induces downregulation of HIF-1α in LNCaP cells,
and found in Fig. 1 that MRV induces apoptosis in LNCaP cells, we
speculated that MRV infection might alter Akt activity. To examine
this possibility, LNCaP cells were mock-infected or infected with
MRV and incubated in normoxic or hypoxic conditions. At 12 and
Fig. 1. MRV infection induces apoptotic cell death in androgen dependent LNCaP cells. LNCaP cells were mock infected or infected with MRV T3D and incubated in normoxic
or hypoxic conditions. (A) At 24 and 48 h p.i., cells were subjected to viability assays. (B) At 24 and 48 h, cells were lysed and caspase 3/7 activity was measured and
expressed relative to total protein. Error bars represent SE of three experimental replicates. Statistically signiﬁcant differences (po0.05) are marked with ‘*’.
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24 h p.i., cells were lysed and proteins were separated on SDS-
PAGE and immunoblotted with antibodies against total Akt,
phosphorylated Akt, and the MRV non-structural protein μNS. At
both 12 and 24 h p.i., and in both normoxic and hypoxic conditions
less P-Akt accumulated in infected cells relative to uninfected cells,
while there were no substantial differences in total Akt protein
levels in these cells (Fig. 2A). Levels of P-Akt relative to β-actin also
demonstrated a signiﬁcant decrease in active Akt in both normoxic
and hypoxic cells by 24 h p.i. Moreover, P-Akt levels in T3D
infected hypoxic cells were signiﬁcantly decreased compared to
levels in normoxic cells at this time p.i. (Fig. 2B). These results
suggest that MRV infection interferes with Akt phosphorylation
and subsequent activity in androgen dependent LNCaP cells grown
in normoxic and especially hypoxic conditions, which may nega-
tively impact the apoptosis resistant phenotype conferred by PTEN
deletion/mutation and hypoxia.
MRV infection induces downregulation of AR protein and activity
Hypoxia has been found to cause increased AR activity by stimulat-
ing its nuclear translocation and increasing its ARE-binding activity
(Park et al., 2006). In addition, P-Akt has been shown to upregulate AR
protein levels (Ha et al., 2011). Our previous ﬁndings that MRV
downregulates HIF-1α in LNCaP and other PCa cells (Gupta-Saraf and
Miller, 2014) coupled with the downregulation of Akt phosphorylation
demonstrated in Fig. 2, led us to hypothesize that MRV infection may
negatively impact the AR. To test this we analyzed AR protein levels
from lysates of uninfected and infected LNCaP cells grown under
hypoxic and normoxic conditions at 12 h and 24 h p.i., by immunoblot
analysis. In these experiments, there were substantially reduced levels
of AR protein in both normoxic and hypoxic MRV infected LNCaP cells
relative to uninfected cells (Fig. 3A and B), suggesting that MRV
infection induces the downregulation of AR protein accumulation in
both normoxic and hypoxic conditions. We additionally examined AR
protein activity during MRV infection by measuring transcription from
an AR dependent ﬁreﬂy luciferase plasmid (pARE-luc) transfected into
mock- and MRV-infected LNCaP cells grown under normoxic and
hypoxic conditions. Conﬁrming our ﬁndings demonstrating decreased
AR protein levels, these assays demonstrated a decrease in AR activity
as measured by luciferase expression in infected cells relative to
uninfected cells in both normoxic and hypoxic conditions (Fig. 3C).
Interestingly, we observed a statistically signiﬁcant increase in AR
activity in non-infected hypoxic LNCaP cells relative to non-infected
normoxic LNCaP cells, a result that supports previously reported HIF-
1αmediated upregulation of AR activity. The MRV-induced decrease in
AR activity in normoxic cells, though repeatable, was modest and not
statistically signiﬁcant. This suggests that MRV-induced downregula-
tion of AR protein only modestly impacts AR activity under normoxic
conditions. Strikingly however, the decrease in AR activity in infected
hypoxic cells relative to non-infected hypoxic cells was substantial and
statistically signiﬁcant, suggesting MRV infection completely overrides
increases in AR activity induced by hypoxia. As similar levels of AR
protein downregulation were seen in MRV-infected cells grown in
normoxic and hypoxic conditions, this may suggest that the down-
regulation of AR activity in infected hypoxic cells is occurring viaMRV-
induced downregulation of HIF-1α instead of virus-induced changes in
AR protein levels.
AR downregulation in MRV infected cells occurs at the translational
level
In an effort to identify the step in AR synthesis that is modulated
during MRV infection, we performed a number of experiments. First,
we examined whether MRV induces proteasome-mediated degrada-
tion of AR by measuring AR protein accumulation in infected cells in
the presence of the proteasome inhibitor MG132. At 12 h p.i.,
uninfected and MRV-infected normoxic and hypoxic LNCaP cells were
treated with MG132 for 12 h prior to harvesting and cell lysis. The
lysate was separated on SDS-PAGE and immunoblotted using AR-
speciﬁc antibodies. HIF-1α, which we have previously demonstrated
to be targeted to the proteasome during MRV infection, was included
as a control to verify MG132 proteasome inhibition. As shown in
Fig. 4A, AR downregulation was not rescued by MG132 in MRV
infected cells indicating that infection does not induce proteasome-
dependent degradation of AR. To determine if MRV infection leads to
decreased transcription of the AR gene, we performed qPCR assays on
total RNA isolated from uninfected and infected LNCaP cells grown
under normoxic and hypoxic conditions at 12 and 24 h p.i. We found
that MRV infection led to signiﬁcantly decreased levels of transcrip-
tion of the AR gene relative to uninfected cells in both normoxic and
hypoxic conditions (Fig. 4B), suggesting MRV may inhibit transcrip-
tion of AR mRNA. However, because the AR gene contains an ARE
regulated by the AR protein, decreased AR mRNA transcription may
occur indirectly as a result of MRV-induced downregulation of AR
protein translation (Dai and Burnstein, 1996). In order to determine if
MRV modulates AR translation, we examined AR protein levels in
MRV-infected BHK cells transiently transfected with a plasmid
expressing a FLAG tagged AR, which does not contain an ARE, and
cannot be transcriptionally regulated by AR. Cell lysates were col-
lected at 12 and 24 h p.i., and immunoblotted for FLAG and MRV non-
structural protein μNS. In agreement with results from endogenous
AR in MRV-infected LNCaP cells, the FLAG-AR protein was down-
regulated in the MRV infected BHK-21 cells relative to uninfected cells
(Fig. 4C). Thus the expression of AR from a FLAG-tagged AR plasmid
Fig. 2. MRV induces decreased levels of Akt activity in LNCaP cells. (A) LNCaP cells
were mock infected or infected with MRV T3D and incubated under normoxic or
hypoxic conditions. At 12 and 24 h p.i., cells were harvested and protein lysates
were separated on SDS-PAGE and transferred to nitrocellulose. Blots were immu-
nostained with rabbit α-phospho Akt, rabbit α-Akt (pan), rabbit α-mNS antiserum,
or mouse α-α-tubulin antibodies followed by AP-conjugated goat α-rabbit or mouse
secondary antibodies. To correct for loading differences between lanes, P-Akt and
Akt bands were quantiﬁed and P-Akt levels relative to Akt were determined.
Calculated levels of P-Akt in infected relative to uninfected cells are shown.
(B) Quantitation of four immunoblots from samples treated as in A, using β-actin
instead of Akt as reference protein.
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Fig. 3. MRV induces downregulation of AR protein and activity in LNCaP cells. (A) LNCaP cells were mock infected or infected with MRV T3D and incubated under normoxic
or hypoxic conditions. At 12 and 24 h p.i., cells were harvested and proteins were separated on SDS-PAGE and transferred to nitrocellulose. Blots were immunostained with
rabbit α-AR antibodies, rabbit α-mNS antiserum, or mouse α-α-tubulin antibodies followed by AP-conjugated goat α-rabbit or mouse secondary antibodies. To correct for
loading differences between lanes, AR and α-tubulin bands were quantiﬁed and AR levels relative to α-tubulin were determined. Calculated levels of AR in infected relative to
uninfected cells are shown. (B) Quantitation of four immunoblots from samples treated as in A, using β-actin instead of α-tubulin as reference protein. (C) LNCaP cells were
transfected with pARE-luc. 24 h post-transfection, cells were mock infected or infected with MRV T3D and incubated in normoxic or hypoxic conditions. At 24 or 48 h p.i.,
luciferase activity and total protein were measured. Relative amounts of luciferase per total protein are shown. Error bars represent SE of three independent experiments.
Statistically signiﬁcant differences (po0.05) are marked with ‘*’.
Fig. 4. AR downregulation in MRV infected cells occurs at the translational level. (A) LNCaP cells were mock infected or infected with MRV T3D and incubated under
normoxic or hypoxic conditions. MG132 was added to cells at 12 h p.i. At 24 h p.i., cells were harvested and proteins separated on SDS-PAGE and transferred to nitrocellulose.
Blots were immunostained with rabbit α-AR antibodies, rabbit α-mNS antiserum, mouse α-HIF-1α antibodies, or mouse α-α-tubulin antibodies followed by AP-conjugated
goat α-rabbit or mouse secondary antibodies. (B) LNCaP cells were mock infected or infected with MRV T3D and incubated under normoxic or hypoxic conditions. At 24 and
48 h p.i., total RNA was isolated and measured using qPCR. Data from three independent experiments are represented as mean7standard error of the mean (SEM).
Statistically signiﬁcant differences (po0.05) are marked with ‘*’. C) BHK-21 cells were transfected with pFLAG-AR. 24 h post-transfection, cells were mock-infected or
infected with MRV T3D and incubated in normoxic or hypoxic conditions. At 12 and 24 h p.i., cells were harvested, proteins separated on SDS-PAGE and transferred to
nitrocellulose. Blots were immunostained with rabbit α-FLAG antibodies, rabbit α-mNS antiserum, or mouse α-α-tubulin antibodies followed by AP-conjugated goat α-rabbit
or mouse secondary antibodies. To correct for loading differences between lanes, FLAG and α-tubulin bands were quantiﬁed and FLAG levels relative to α-tubulin were
determined. Calculated levels of FLAG in infected relative to uninfected cells are shown. (D) BHK-21 cells were transfected with pFLAG-AR. 24 h post-transfection, cells were
mock infected or infected with MRV T3D and incubated in normoxic or hypoxic conditions. MG132 was added to cells at 8 h p.i. At 12 h and 24 h p.i., cells were harvested,
proteins separated on SDS-PAGE and transferred to nitrocellulose. Blots were immunostained with rabbit α-FLAG antibodies, rabbit α-mNS antiserum, or mouse α-α-tubulin
antibodies followed by AP-conjugated goat α-rabbit or mouse secondary antibodies.
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that does not contain an ARE in its promoter is still diminished by
MRV infection suggesting that the downregulation of AR protein in
MRV infected cells occurs primarily via inhibition of protein transla-
tion. This decrease in AR protein likely contributes substantially to the
loss of AR mRNA transcription measured in Fig. 4B. To conﬁrm that
FLAG-tagged AR protein downregulation during MRV infection is
independent of proteasome-mediated degradation; we examined
FLAG-AR accumulation in infected cells in the presence of MG132.
BHK-21 cells transfected with the plasmid expressing FLAG-AR were
mock infected or infected with MRV, and MG132 was added at 8 h p.i.
Lysate was collected either at 12 or 24 h p.i., and immunostained with
anti-FLAG antibodies. Consistent with results from the endogenous
AR protein, MG132 was unable to rescue the FLAG-AR in MRV
infected cells (Fig. 4D). Taken together, this data suggests that MRV
downregulates AR by inhibiting its translation, which subsequently
results in AR mRNA transcription downregulation.
MRV infection induces reduced PSA levels
The expression of prostate speciﬁc antigen (PSA) is dependent
on androgen signaling and has been used extensively as a marker
of PCa growth. The binding of AR to AREs in the proximal promoter
and a distal enhancer of the PSA gene, results in its transcription
regulation (Cleutjens et al., 1996; Farmer et al., 2001). In addition,
the PSA gene promoter region also contains a hypoxia response
element (HRE), which is essential for HIF-1 binding in response to
hypoxia (Horii et al., 2007). HIF-1 interacts with AR on this region
of the PSA gene to activate its expression under hypoxic conditions
(Horii et al., 2007). Since MRV infection causes downregulation of
HIF-1α (Gupta-Saraf and Miller, 2014) and AR protein accumula-
tion and activity (Figs. 3 and 4), we reasoned that PSA levels in
MRV infected cells may also be impacted. To test this, LNCaP cells
were infected with MRV or mock infected and incubated under
normoxic and hypoxic conditions for 12 and 24 h p.i. Harvested
cell lysates were separated on SDS-PAGE and immunoblotted with
anti-PSA antibodies. Similar to what was seen in AR experiments,
PSA protein levels were reduced in MRV infected normoxic and
hypoxic cells (Fig. 5A and B). Since PSA secreted in the serum is a
direct measure for PCa diagnosis and monitoring, we also mea-
sured secreted PSA from uninfected and MRV infected LNCaP cells
growing under normoxic and hypoxic conditions using ELISA. In
this assay, secreted PSA was also reduced in MRV infected,
normoxic and hypoxic cells relative to uninfected cells conﬁrming
that MRV infection induces downregulation of PSA (Fig. 5C).
Interestingly, the downregulation of the levels of secreted PSA
were more drastic in MRV-infected hypoxic cells relative to MRV-
infected normoxic cells. As PSA expression is regulated by both AR
and HIF-1α, this enhanced downregulation of PSA secretion in
hypoxic, infected cells may occur as a result of the downregulation
of both AR and HIF-1α proteins by MRV (this study and (Gupta-
Saraf and Miller, 2014)).
In order to determine if the decrease in PSA protein was the result
of MRV-induced AR/HIF-1α downregulation or whether MRV infec-
tion induced the downregulation of PSA via a different route, we
created a FLAG tagged PSA expression construct, which does not
contain either an ARE or HRE. BHK-21 cells were transfected with a
plasmid expressing FLAG-PSA, then mock infected or infected with
MRV, and at 24 h p.i., cells were harvested and proteins separated on
SDS-PAGE and immunoblotted. In these experiments, MRV-infection
was able to downregulate PSA; however, the downregulation was not
as pronounced as that seen with endogenous PSA, which contains an
ARE and HRE (Fig. 5D). Altogether, these data suggest that MRV
infection can induce downregulation of PSA by repressing AR and/or
HIF-1α activity and also by an AR/HIF-1α independent mechanism.
Discussion
Most current ﬁrst-line prostate tumor therapies are based on
androgen deprivation. Although effective for an average of three
years after treatment onset, the emergence of androgen indepen-
dent CRPC is inevitable. At the CRPC disease stage, docetaxel with
prednisone is the most common therapy option. For docetaxel-
refractory metastatic CRPC, another line of treatment includes
cabazitaxel or abiraterone in combination with prednisone (Maluf
et al., 2012). A number of other drugs have also been approved by
the Food and Drug Administration (FDA) for the treatment of
CRPC, but despite this progress, it still remains a lethal disease
with an estimated 30,000 deaths occurring in the USA in 2014
(Siegel et al., 2014). Identiﬁcation of treatment options that may be
efﬁcacious during the different disease and treatment stages of
PCa is critical.
Prostate tumor cells appear to use Akt activity to stimulate growth
independent of the AR when subjected to androgen deprivation
(Mikhailova et al., 2008). We have found that MRV is able to down-
regulate P-Akt in cells that have not progressed to androgen indepen-
dence, suggesting MRV may block the AR independent growth signal
needed for prostate tumors to survive androgen ablation therapy.
Moreover, Akt activity has also been associated with resistance to
TRAIL induced apoptosis in LNCaP cells (Nesterov et al., 2001), and
causes phosphorylation of pro-apoptotic protein BAD and thus inhibits
apoptosis (Datta et al., 1997). We also show that MRV infection induces
apoptosis and cell death of androgen dependent cells growing in
normoxic and hypoxic conditions. MRV downregulation of Akt activity
may therefore contribute to apoptosis induction in these cells. MRV
induction of caspases and subsequent apoptosis in androgen depen-
dent PCa cells, whether or not it is mediated through downregulation
of Akt activity, support the continued exploration of MRV as a critically
needed therapeutic for inducing cell death of androgen-dependent
PCa and CRPC targeting androgen-independent pathways.
Androgen independent prostate tumors remain AR dependent
(Feldman and Feldman, 2001) because they maintain functional AR
signaling, even under very low androgen levels. Mechanisms behind
maintenance of AR dependence post androgen independence include
1) the overexpression or gene ampliﬁcation of the AR (Latil et al.,
2001; Linja et al., 2001; Visakorpi et al., 1995), making even small
amounts of hormone sufﬁcient for growth, and 2) mutations in AR
treated with anti-androgens, which may broaden ligand speciﬁcity
(Marcelli et al., 2000; Veldscholte et al., 1990). Additionally, studies
have linked the AR with the emergence of androgen independent
cells by demonstrating that ectopic expression of high levels of AR can
transform androgen dependent cells to androgen independence
(Chen et al., 2004). Thus the work presented in this study, which
shows that MRV downregulates AR protein levels and activity,
support future studies examining the possibility that this virus may
encode useful proteins or induce cellular changes that could be
exploited as a therapeutic option to target AR.
Hypoxia increases the activity and sensitivity of AR (Park et al.,
2006) and consequently may trigger the selection of androgen
independent phenotypes (Butterworth et al., 2008; Chen et al.,
2004). Androgen ablation therapy has also been show to induce
hypoxia in prostate tumor cells (Ming et al., 2013). Because of the key
role played by AR in the development of prostate tumors and the link
between hypoxia and PCa progression, it is important to identify
therapies that target androgen dependent prostate tumor cells and
AR under both normoxic and hypoxic conditions. In this study, we
have established that MRV downregulates AR protein and activity and
secreted PSA levels under normoxic as well as hypoxic conditions.
Additional work determining the speciﬁc mechanisms of HIF-1α and
AR downregulation during MRV infection may identify novel viral
derived therapies that interfere with AR activity under hypoxic
conditions.
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The hypothesis for this study was based on the rationale that
because MRV infection induces the downregulation of HIF-1α, that
this virus may modulate regulatory proteins involved in progres-
sion of PCa cells to androgen independence that are also modu-
lated under hypoxic growth conditions. We found that MRV
infection results in decreased accumulation of activated Akt, AR
protein and activity, and total and secreted PSA protein in both
normoxic and hypoxic PCa cells, suggesting that even in the
absence of hypoxia, MRV infection alters the expression and
activity of proteins involved in progression to androgen indepen-
dence. However, in our experiments, there were substantially
greater decreases in Akt and AR activity and PSA levels in infected
cells grown in hypoxic relative to normoxic conditions (Figs. 2B, 3C
and 5C), supporting the original hypothesis that HIF-1α protein
downregulation by MRV may modulate proteins involved in
progression to androgen independence when PCa cells are grow-
ing in hypoxic microenvironments. However, these results do not
deﬁne the involvement of HIF-1α in the downregulation of these
proteins during MRV infection, and further investigation is needed
to directly examine the role of MRV-induced HIF-1α downregula-
tion on the expression and activity of Akt, AR, and PSA.
MRV's oncolytic properties have been tested in clinical trials and in
in vivomouse models for PCa (Thirukkumaran et al., 2010; Vidal et al.,
2008). MRV induced reduction in tumor size in SCID/NOD mice
following only a single intratumoral injection. In human patients,
MRV also demonstrated antitumor activity by reducing tumor size
with minimal side effects (Thirukkumaran et al., 2010). MRV has also
been shown to confer anti-PCa immunity by initiating a strong T-cell
response towards the tumor cells (Gujar et al., 2011). Furthermore,
MRV works in synergism in vitro and in animal studies with
docetaxel, which is used widely for CRPC treatment (Heinemann
et al., 2011), and induces the downregulation of HIF-1α, an important
driver of prostate tumor progression (Gupta-Saraf andMiller, 2014). In
this study we provide evidence that MRV may also impact progres-
sion to more advanced stages of PCa disease progression by 1)
downregulating Akt activity, 2) downregulating AR protein levels
and activity, and 3) inducing apoptosis and causing cell death of
androgen dependent PCa cells growing in normoxic and hypoxic
microenvironments. Because MRV infection kills the majority of
infected cells via apoptosis during the ﬁrst 48 h of infection (Fig. 1),
and we did not observe downregulation of AR or PSA in bystander
non-infected cells (data not shown), it is unlikely that wildtype MRV
infection would be a useful therapy to prevent progression to CRPC.
However, this data provides a rationale for future molecular dissection
of the mechanism behind MRV modulation of Akt and AR activity in
normoxic and hypoxic conditions, such that speciﬁc viral proteins or
virus-induced cellular changes may be identiﬁed that modulate Akt,
AR, and PSA activity which may have the capacity to delay or interfere
with progression to this highly aggressive and metastatic form of
disease, for which treatment options remain limited.
Material and methods
Cells and reagents
LNCaP cells were maintained in RPMI media (ATCC), containing 10%
fetal bovine serum (Atlanta Biologicals) and penicillin-streptomycin
(100 IU/ml, Mediatech). BHK-21 cells were maintained in DMEM
(Sigma) containing 10% fetal bovine serum (Atlanta Biologicals),
penicillin-streptomycin (100 IU/ml, Mediatech), L-Glutamine (2 nM,
Mediatech) and 1% Non-Essential Amino acids (Invitrogen). Primary
antibodies used were as follows: rabbit monoclonal anti-AR (catalog
#5153), rabbit monoclonal anti-PSA (catalog #5365), rabbit monoclonal
Fig. 5. MRV infection induces reduced PSA protein expression and secretion. (A) LNCaP cells were mock infected or infected with MRV T3D and incubated under normoxic or
hypoxic conditions. At 12 and 24 h p.i., cells were harvested and proteins were separated on SDS-PAGE and transferred to nitrocellulose. Blots were immunostained with
rabbit α-PSA antibodies, rabbit α-μNS antiserum, or mouse α-α-tubulin antibodies followed by AP-conjugated goat α-rabbit or mouse secondary antibodies. To correct for
loading differences between lanes, PSA and α-tubulin bands were quantiﬁed and PSA levels relative to α-tubulin were determined. Calculated levels of PSA in infected relative
to uninfected cells are shown. (B) Quantitation of four immunoblots from samples treated as in A, using β-actin instead of α-tubulin as reference protein. (C) LNCaP cells were
mock infected or infected with MRV T3D and incubated under normoxic or hypoxic conditions. At 12 and 24 h p.i., media from the plates was collected and total PSA
measured using ELISA, then cells were lysed and total protein was measured by Bradford assay. Relative amounts of PSA per total protein are shown. Error bars represent SE
of three experimental replicates. Statistically signiﬁcant differences (po0.05) are marked with ‘*’. (D) BHK-21 cells were transfected with pFLAG-PSA. 24 h post-transfection,
cells were mock infected or infected with MRV T3D and incubated in normoxic or hypoxic conditions. At 12 and 24 h p.i., cells were harvested and proteins were separated
on SDS-PAGE and transferred to nitrocellulose. Blots were immunostained with rabbit α-FLAG antibodies, rabbit α-mNS antiserum, or mouse α-α-tubulin antibodies followed
by AP-conjugated goat α-rabbit or mouse secondary antibodies. To correct for loading differences between lanes, FLAG and α-tubulin bands were quantiﬁed and FLAG levels
relative to α-tubulin were determined. Calculated levels of FLAG in infected relative to uninfected cells are shown.
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anti-Akt (catalog #4685), rabbit monoclonal anti-phospho-Akt (catalog
#4060), rabbit polyclonal anti-FLAG (catalog #2368) (Cell Signaling
Technologies), mouse monoclonal anti-HIF-1α (catalog #610958, BD
Biosciences), mouse polyclonal anti-α-tubulin (catalog #T6074, Sigma)
and rabbit polyclonal anti-μNS (Qin et al., 2009). Secondary antibodies
used for immunoblot experiments were alkaline phosphatase (AP)-
conjugated goat anti-mouse (catalog #1706520) or anti-rabbit IgG
(catalog #170–6518, Bio-Rad). Proteasome inhibitor, MG132 (Enzo Life
Sciences), was used at a ﬁnal concentration of 10 mM.
Infection
MRV virions (T3D strain) are from our laboratory stocks. Puriﬁed
virions were prepared as described (Mendez et al., 2000), using
Vertrel reagent (DuPont) in place of Freon, and stored in dialysis
buffer (150 mM NaCl; 10 mM Tris pH 7.4; 10 mMMgCl2) at 4 1C. Cells
were seeded onto 60-mm, 35-mm, or 9.6-cm2 cell culture dishes 24 h
before infection. Cells were infected with MRV virions at a cell
infectious unit (CIU) of 1 based on titers determined on cell lines
used as previously described (Qin et al., 2011).
Hypoxia
Hypoxic conditions were obtained by incubating cells in 1% O2
and 5% CO2 at 37 1C in a Galaxy 48R CO2 Incubator (New
Brunswick Scientiﬁc) equipped with 1–19% O2 controls. All cells
were adapted to hypoxia for 4 h prior to infection.
Immunoblotting
Cells were lysed in 100 μL 2X SDS protein loading buffer (125 mM
Tris HCl [pH 6.8], 200 mM DTT, 4% SDS, 0.2% Bromophenol blue, 20%
Glycerol). Immunoblots were performed as previously described (Qin
et al., 2011). Blots were exposed to Lumi-Phos™ WB Chemilumines-
cent Substrate (Thermo Scientiﬁc), and images were collected and
quantiﬁed using a ChemiDoc XRS camera and QuantityOne software
(Bio-Rad). All experiments were independently performed at least
3 times and representative results are shown.
Plasmid construction
To create pARE-Luc, a ﬁreﬂy luciferase reporter plasmid (pGL4.26
luc2/minP/Hygro) was purchased from Promega. Upper and lower
oligonucleotides were designed which contain three copies of the
androgen response element, 50 GTACGTGCT 30, ﬂanked on each end by
NheI and HindIII restriction sites (New England Biolabs). Oligonucleo-
tides were annealed and ligated into NheI and HindIII digested
pGL4.26 luc2/minP/Hygro. To create FLAG-tagged AR and PSA expres-
sion plasmids, a gene speciﬁc forward primer containing the FLAG
sequence ﬂanked by an NheI restriction site and a gene speciﬁc
reverse primer ﬂanked by an XbaI restriction sites were used to
amplify the AR and PSA genes using plasmids pEGFP-C1-AR (Addgene
plasmid 28235, (Stenoien et al., 1999)) and pCMV6-AC-PSA (SC324412,
Origene) as templates. The resulting PCR product was digested and
ligated into NheI/XbaI digested pCI-Neo. Following ligation, transfor-
mation, and screening, all plasmids were veriﬁed by sequencing.
Luciferase assay
Cells were transfected with pARE-luciferase using Lipofectamine
2000 (Invitrogen) according to the supplier's protocol. Luciferase
expression was measured using the One-Glo Luciferase Assay Kit
and the luminescence function of a GloMaxMultiþ microplate reader
(Promega). Following recording of luminescence, cells were lysed and
total protein was measured using Bradford Assay (Biorad) and the
absorbance function of a GloMax Multiþ microplate reader.
Luminescence levels were normalized to total protein and plotted
on a graph. Results shown are means and standard error of three
experimental replicates. The statistical signiﬁcance was calculated
using the average of 3 experimental replicates.
PSA ELISA
ELISA test was performed using the Total PSA ELISA kit from
DRG International, according to the manufacturer's instruction.
The color intensity (optical density) was measured using a GloMax
Multiþ microplate reader and is directly proportional to the
amount of antigen in the sample. The cells were lysed and total
protein measured using Bradford Assay (Biorad) and the absor-
bance function of a GloMax Multiþ microplate reader. PSA levels
were normalized to total protein and plotted on a graph. Results
shown are means and standard error of three experimental
replicates, each with duplicate samples.
Cell viability and caspase activity assay
Cell viability assays were performed using the Cell-Titer Blue
Viability Assay and Caspase activity was measured using Caspase 3/
7 Glo Assay from Promega, according to the manufacturer's instruc-
tion. Fluorescence for the viability assay was measured using the
GloMax Multiþ microplate reader and the values were plotted on a
graph, with error bars depicting standard error. Following recording
of luminescence for caspase assay, cells were lysed and total protein
was measured using Bradford Assay (Biorad). Luminescence levels
were normalized to total protein and plotted on a graph. The
experiments were performed independently thrice and each experi-
ment had 3 replicates of each sample.
Quantitative real-time PCR
RNA was harvested using Trizol (Invitrogen) or Zyppy Direct-
zol RNA miniprep kit as per manufacturer's instruction. 100 ng of
RNA was subjected to qPCR using Power SYBR Green RNA-to-CT 1-
step Kit from Applied Biosystems as per manufacture's protocol.
Primers used were as follows: β-actin (409 bp): forward primer
ACCAACTGGGACGACATGGAGAAA, reverse primer, TTAATGTCACG-
CACGATTTCCCGC; AR (168 bp): forward primer CCTGGCTT
CCGCAACTTACAC, reverse primer GGACTTGTGCATGCGGTACTCA.
β-actin CT values were used as a control and infected samples
were normalized to uninfected samples in each condition. Fold
differences were calculated using the PfaffI method. The experi-
ment was done thrice independently and each experiment
included 2 sample replicates. The average of the three experiments
was plotted on a bar graph with error bars depicting the standard
error of the averages.
Statistical analysis
Statistical signiﬁcance was determined using student's t-test
and two-tailed p value calculated with GraphPad software. Differ-
ences in groups for which po0.05 were considered to be statis-
tically signiﬁcant and are indicated with an asterisk in ﬁgures.
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